Research programme: AGE Formation Inhibitors - SynvistaAlternative Names: ALT-946
Latest Information Update: 07 Apr 2009
At a glance
- Originator Alteon
- Developer Synvista Therapeutics
- Class Acetamides; Antihyperglycaemics; Hydrazines; Small molecules
- Mechanism of Action Advanced glycosylation end product inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic nephropathies